News and EventsNews First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-2522 December, 2025 Xinnate Completes Oversubscribed Share Issue of SEK 38,5m18 December, 2025 Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa10 December, 2025 Xinnate raises SEK 31 million in oversubscribed share issue1 July, 2025 New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD27 June, 2025 Xinnate announces successful FDA meeting for TCP-2523 May, 2025 Xinnate receives Orphan Drug Designation from US FDA for TCP-2514 January, 2025 Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm17 December, 2024 Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa27 September, 2024 Xinnate presents TCP-25 data at international dermatology congress5 September, 2024 ALL NEWSEvents EB 2026: 20-22 Jan 2026 EB Awareness week: 25-31 Oct 2025 NLS Days: 13-14 Oct 2025 ESDR MEETING: 10-13 Sep 2025 ALL EVENTSPress Releases First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-2522 December, 2025 Xinnate Completes Oversubscribed Share Issue of SEK 38,5m18 December, 2025 Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa10 December, 2025 ALL PRESS RELEASES
